scholarly journals The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

Leukemia ◽  
2010 ◽  
Vol 25 (2) ◽  
pp. 246-253 ◽  
Author(s):  
W-C Chou ◽  
W-C Lei ◽  
B-S Ko ◽  
H-A Hou ◽  
C-Y Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Isocitrate Dehydrogenase ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Prognostic Impact ◽  
Isocitrate Dehydrogenase 2 ◽  
Acute Myeloid

scholarly journals Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

2014 ◽  
Vol 2 (1) ◽  
Author(s):  
Kerstin Willander ◽  
Ingrid Jakobsen Falk ◽  
Roza Chaireti ◽  
Esbjörn Paul ◽  
Monica Hermansson ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Isocitrate Dehydrogenase ◽  
Myeloid Leukemia ◽  
Prognostic Value ◽  
Isocitrate Dehydrogenase 2 ◽  
Acute Myeloid

Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

2010 ◽  
Vol 28 (23) ◽  
pp. 3717-3723 ◽  
Author(s):  
Nicolas Boissel ◽  
Olivier Nibourel ◽  
Aline Renneville ◽  
Claude Gardin ◽  
Oumedaly Reman ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Leukemia ◽  
Isocitrate Dehydrogenase ◽  
Myeloid Leukemia ◽  
Prognostic Impact ◽  
Dehydrogenase Enzyme ◽  
Induction Failure ◽  
Wbc Count ◽  
French Association ◽  
Acute Myeloid

Purpose Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously reported to be involved in gliomas as well as IDH2 mutations (IDH2m). The prognosis of both IDH1m and IDH2m in AML remains unclear. Patients and Methods The prevalence and the prognostic impact of R132 IDH1 and R172 IDH2 mutations were evaluated in a cohort of 520 adults with AML homogeneously treated in the French Acute Leukemia French Association (ALFA) -9801 and -9802 trials. Results The prevalence of IDH1m and IDH2m was 9.6% and 3.0%, respectively, mostly associated with normal cytogenetics (CN). In patients with CN-AML, IDH1m were associated with NPM1m (P = .008), but exclusive of CEBPAm (P = .03). In contrary, no other mutations were detected in IDH2m patients. In CN-AML patients, IDH1m were found in 19% of favorable genotype ([NPM1m or CEBPAm] without fms-related tyrosine kinase 3 [FLT3] internal tandem duplication [ITD]) and were associated with a higher risk of relapse (RR) and a shorter overall survival (OS). Favorable genotype in CN-AML could thus be defined by the association of NPM1m or CEBPAm with neither FLT3-ITD nor IDH1m. In IDH2m CN-AML patients, we observed a higher risk of induction failure, a higher RR and a shorter OS. In multivariate analysis, age, WBC count, the four-gene favorable genotype and IDH2m were independently associated with a higher RR and a shorter OS. Conclusion Contrarily to what is reported in gliomas, IDH1m and IDH2m in AML are associated with a poor prognosis. Screening of IDH1m could help to identify high-risk patients within the subset of CN-AML with a favorable genotype.

Prognostic Impact ofNPM1Mutations in Serbian Adult Patients with Acute Myeloid Leukemia

2012 ◽  
Vol 128 (4) ◽  
pp. 203-212 ◽  
Author(s):  
Milos Kuzmanovic ◽  
Natasa Tosic ◽  
Natasa Colovic ◽  
Teodora Karan-Djurasevic ◽  
Vesna Spasovski ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Prognostic Impact ◽  
Acute Myeloid

scholarly journals PROGNOSTIC IMPACT OF ISOCITRATE DEHYDROGENASE ENZYME ISOFORMS IDH1 & IDH2 MUTATIONS IN ACUTE MYELOID LEUKEMIA

2019 ◽  
Vol 70 (10) ◽  
pp. 623-633
Author(s):  
Sahar Abd El Maksoud ◽  
Rasha ElGamal ◽  
Shaimaa Pessar ◽  
Hanaa Abd El-Samee ◽  
Dalia Salem ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Isocitrate Dehydrogenase ◽  
Myeloid Leukemia ◽  
Prognostic Impact ◽  
Dehydrogenase Enzyme ◽  
Enzyme Isoforms ◽  
Acute Myeloid

scholarly journals HOTAIR expression and prognostic impact in acute myeloid leukemia patients

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Rawda Ahmed Alaa Eldin ◽  
Amany Ahmed Osman ◽  
Mona Fathey Abdel Fattah Hassan ◽  
Shereen Abdel Monem Ibrahim ◽  
Yasmin Nabil El-Sakhawy
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Mononuclear Cells ◽  
Diagnostic Marker ◽  
Adult Patients ◽  
Prognostic Impact ◽  
Newly Diagnosed ◽  
Prognostic Variables ◽  
Acute Myeloid

Abstract Background Acute myeloid leukemia (AML) is a disorder characterized by a rapid onset of symptoms attributable to bone marrow failure due to clonal proliferation of primitive hematopoietic stem cells or progenitor cells. Epigenetic abnormalities play an important role in the development and progression of acute leukemia. Long non-coding ribonucleic acid (lncRNA) plays an important role in epigenetic regulation. Homeobox (Hox) transcript antisense intergenic RNA (HOTAIR) is a lncRNA which has been determined to be a negative prognostic indicator in various solid-tumor patients. However, its role in hematopoietic tumors as AML is to be assessed. This study aimed at measuring lncRNA HOTAIR expression level on bone marrow (BM) mononuclear cells in newly diagnosed AML patients and correlating its expression with their outcome and different prognostic variables. This provides new prospective for a novel marker involved in development and progression of AML which can be used as a diagnostic marker and a target of therapy. The current study included 65 subjects divided into 35 newly diagnosed AML adult patients (before initiation of chemotherapy) and 30 non-leukemic adult patients who are candidates for BM aspiration for causes other than hematological malignancies as immune thrombocytopenic purpura and hypersplenism as controls. HOTAIR expression was measured on BM mononuclear cells by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results HOTAIR expression was found to be significantly upregulated in AML patients (probability (p) value = 0.000) and it can be used as a diagnostic biomarker of AML as confirmed by a significant difference between cases and controls using receiver operating characteristic curve (ROC) analysis. However, it was not significantly correlated with event free survival (EFS) or prognostic variables. Conclusion This study showed that the expression of HOTAIR is upregulated in de novo AML patients and can be used as a diagnostic marker. However, highly expressed HOTAIR is not associated with poor prognosis.

HighEVI1Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

2010 ◽  
Vol 28 (12) ◽  
pp. 2101-2107 ◽  
Author(s):  
Stefan Gröschel ◽  
Sanne Lugthart ◽  
Richard F. Schlenk ◽  
Peter J.M. Valk ◽  
Karina Eiwen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Splice Variants ◽  
Quantitative Polymerase Chain Reaction ◽  
Prognostic Significance ◽  
Adult Patients ◽  
Prognostic Impact ◽  
Monosomy 7 ◽  
Free Survival ◽  
Acute Myeloid

PurposeThe purpose of this study was to investigate frequency and prognostic significance of high EVI1 expression in acute myeloid leukemia (AML).Patients and MethodsA diagnostic assay detecting multiple EVI1 splice variants was developed to determine the relative EVI1 expression by single real-time quantitative polymerase chain reaction in 1,382 newly diagnosed adult patients with AML younger than 60 years. Patients were treated on four Dutch-Belgian HOVON (n = 458) and two German-Austrian AML Study Group protocols (n = 924).ResultsThe EVI1 assay was tested in the HOVON cohort and validated in the AMLSG cohort. High EVI1 levels (EVI1+) were found with similar frequencies in both cohorts combined, with a 10.7% incidence (148 of 1,382). EVI1+independently predicted low complete remission (CR) rate (odds ratio, 0.54; P = .002), adverse relapse-free survival (RFS; hazard ratio [HR], 1.32; P = .05), and event-free survival (EFS; HR, 1.46; P < .001). This adverse prognostic impact was more pronounced in the intermediate cytogenetic risk group (EFS; HR, 1.64; P < .001; and RFS; HR, 1.55; P = .02), and was also apparent in cytogenetically normal AML (EFS; HR, 1.67; P = .008). Besides inv(3)/t(3;3), EVI1+was significantly associated with chromosome abnormalities monosomy 7 and t(11q23), conferring prognostic impact within these two cytogenetic subsets. EVI1+was virtually absent in favorable-risk AML and AML with NPM1 mutations. Patients with EVI1+AML (n = 28) who received allogeneic stem cell transplantation in first CR had significantly better 5-year RFS (33% ± 10% v 0%).ConclusionEVI1 expression in AML is unequally distributed in cytogenetic subtypes. It predicts poor outcome, particularly among intermediate cytogenetic risk AML. Patients with EVI1+AML may benefit from allogeneic transplantation in first CR. Pretreatment EVI1 screening should be included in risk stratification.

Sign in / Sign up

Export Citation Format

Share Document